CD19 and cancer: Jurkat cells expressing the MC.27.759S TCR responded to multiple cancer cell lines that naturally expressed either MR1*01 or MR1*02 but did not respond toward healthy CD14+ monocytes or CD19+ B cells from 3 donors (Figure 2G).